The rise of Precision Medicine and the brain
– –

Innovations driving Precision Medicine — genomics, high-resolution imaging and other technologies, big data and rigorous medical research — are transforming diagnosis and treatments of diseases across all areas of medicine.

Now, under a limited regulatory clearance from the FDA, commercially-available personal genomic mapping services allow consumers to see if they carry genetic markers associated with risks for certain health conditions, including Parkinson’s Disease and late-onset Alzheimer’s Disease, among others.

Early can make all the difference
– –

When it comes to degenerative brain diseases like Parkinson’s, dementia and other dopamine-related diseases, early detection matters.

After all, degenerative brain diseases can progress for up to 20 years before detectable symptoms appear. The challenge in diagnosing these conditions is that the number of viable dopaminergic neurons is significantly depleted by the time symptoms are evident—at which point intervention may be too late.

In the absence of reliable biomarkers, visualizing and quantifying changes in the brain as early as possible is the best way to enable the development of predictive tests and disease modifying therapies.

Hope for actionable insights
– –

Early, precise views of nuanced dopamine receptor activity in the brain are critical to actionable therapies for patients with degenerative brain disease. Access to novel interventions such as deep Brain Stimulation surgery or MRI guided focused ultrasound system for tremor elimination combined with an expanding pipeline of disease modifying drugs will exponentially increase the demand for accurate, affordable and timely diagnosis.

© 2017 LikeMinds | All Rights Reserved.